Evidence map›Paper›PMID 42773934›Full record

ReviewMolecular oncology2026

Cancer-associated mutations in endometriosis reframe a benign disease through molecular oncology.

Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Clarissa MujacicDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.ORCID https://orcid.org/0009-0002-1748-6337
Maria Concetta VitaleDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.
Rita SiinoDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.
Emilia Di GiovanniDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.
Carla Ferrante BanneraDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.
Enrico Di MarcoDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.
Andrea GottardoDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.
Tancredi Didier Bazan RussoDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.
Nadia BarracoDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.
Alessandro PerezDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.
Valerio GristinaDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.
Antonio GalvanoDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.
Giuseppe BadalamentiDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.
Antonio RussoDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.ORCID https://orcid.org/0000-0002-4370-2008
Viviana BazanDepartment of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Section of Medical Oncology, University of Palermo, Italy.
Lorena IncorvaiaDepartment of Precision Medicine in Surgical, Oncological, and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometriosis is a benign yet debilitating condition, and its molecular complexity remains unexplored. Although clinically recognized, its genetic landscape has long been overlooked. This review analyses cancer-associated mutations (CAMs) identified in endometriotic lesions, revealing parallels with malignancy. Recurrent mutations in key oncogenic and tumour suppressor genes-PIK3CA, CTNNB1, KRAS, PTEN and ARID1A-emerge with patterns distinct from cancer, yet suggesting shared mechanisms. Despite the limited genomic data, these findings position endometriosis as a valuable model for investigating early tumour-like processes. By reframing endometriosis through the lens of molecular oncology, this study offers new insights into its pathogenesis and proposes a translational framework for advancing diagnostics and understanding disease progression at the benign-malignant interface.

Indexed as

cancer‐associated mutationsendometriosisgynaecological cancermolecular pathologyoncogenic pathwaysprecision medicine

Identifiers

PMID42773934
PMCPMC13598555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.